Parenteral Drug Association

Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024

Retrieved on: 
Tuesday, March 19, 2024
Automation, QA/QC, PDA, Parenteral Drug Association, Convention, Growth, Consultant, Annual general meeting, Critical, Medical device

This year’s PDA Annual Meeting is at the core of the inaugural PDA Week that features many events including training, roundtables, presentations and tours that address the opportunities and challenges most relevant to the future of pharmaceutical microbiology.

Key Points: 
  • This year’s PDA Annual Meeting is at the core of the inaugural PDA Week that features many events including training, roundtables, presentations and tours that address the opportunities and challenges most relevant to the future of pharmaceutical microbiology.
  • Attendees will include global microbiology and QA/QC process professionals, regulators, academia and pharmaceutical industry consultants.
  • Rapid Micro’s booth, #435, will showcase the benefits of automating microbial quality control (“MQC”) testing using the Growth Direct® System software and technology for rapid incubation, detection and enumeration.
  • The presentation will include information on the new Growth Direct® Rapid Sterility Application, which is the only fully automated, non-destructive, growth-based platform for sterility testing.

PDA Announces the Jette Christensen Early Career Professional Grant in Memory of Past PDA Chair

Retrieved on: 
Thursday, November 9, 2023
Courage, Chairperson, Patient, Multimedia, Science, PDAF, Parenteral Drug Association, Conference, Attitude, Cancer, PDA, Memory, Education, Satellite navigation device, Nursing, Management, Pharmaceutical industry, Research

BETHESDA, Md., Nov. 9, 2023 /PRNewswire-PRWeb/ -- PDA today announced the establishment of the Jette Christensen Early Career Professional Grant in memory of the Immediate-Past Chair of the PDA Board of Directors, who passed away on October 24 after a long battle with cancer. As a PDA member, Board Member, and PDA Chair, Jette's dedication to PDA's mission of advancing pharmaceutical/biopharmaceutical manufacturing science and regulation so members can better serve patients benefited not only PDA members but the entire industry.

Key Points: 
  • BETHESDA, Md., Nov. 9, 2023 /PRNewswire-PRWeb/ -- PDA today announced the establishment of the Jette Christensen Early Career Professional Grant in memory of the Immediate-Past Chair of the PDA Board of Directors, who passed away on October 24 after a long battle with cancer.
  • Created through the PDA Foundation for Pharmaceutical Education, Training, and Research, the Jette Christensen Early Career Professional Grant will provide funding for the development of the next generation of industry leaders which is reflective of one of Jette's many passions.
  • Early Career Professionals selected to receive this prestigious developmental grant will receive funding to enable their attendance at PDA's technical conferences and training courses.
  • "The PDA organization is very saddened by the recent loss of our Immediate Past Chair and long-term PDA Member Jette Christensen," said Glenn Wright, PDA President and CEO.

PDA Announces 2023 Drug Delivery Innovation Award Winners at Universe of Pre-Filled Syringes Conference

Retrieved on: 
Tuesday, October 17, 2023
Universe, Chicago Innovation Awards, Partnership, ANSI, Stevanato Group, Parenteral Drug Association, PDA, Automation, Caregiver, WMG, University of Warwick, Digital platform, Global Smoke-Free Partnership Award, Organization, Limited partnership, Bayer, Ecosystem, Education, Merck, Science, PFS, Syringe, Patient, Diluent, Pharmaceutical industry, EU

BETHESDA, Md., Oct. 17, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) today announced the winners of the 2023 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices conference in Gothenburg, Sweden. Awardees were recognized for their technical innovations in advancing the field of bio/pharmaceutical manufacturing.

Key Points: 
  • BETHESDA, Md., Oct. 17, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) today announced the winners of the 2023 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices conference in Gothenburg, Sweden.
  • The companies recognized for the 2023 PDA Drug Delivery Innovation Awards are well-deserving of this honor and I congratulate them for their achievements and tireless effort to move the industry forward.
  • PDA recognizes the award winners each year at its annual Universe of Pre-Filled Syringes and Injection Devices conference, which is held in the U.S. in even years and the EU in odd years.
  • The PDA Drug Delivery Innovation Awards were created in 2019 to recognize technical innovations advancing the field of bio/pharmaceutical manufacturing.

Rapid Micro Biosystems to Exhibit at the 2023 PDA Pharmaceutical Microbiology Conference from October 2 – 4

Retrieved on: 
Friday, September 29, 2023
Microbiology, Parenteral Drug Association, MBA, QA/QC, Automation, Consultant, Mold, Master of Science, Growth, Conference, Platinum, Pharmaceutical industry, Risk management

This year’s conference will continue the ongoing tradition of addressing the opportunities and challenges most relevant to the future of pharmaceutical microbiology.

Key Points: 
  • This year’s conference will continue the ongoing tradition of addressing the opportunities and challenges most relevant to the future of pharmaceutical microbiology.
  • Attendees will include global microbiology and QA/QC process professionals, regulators, academia and pharmaceutical industry consultants.
  • “We are proud to continue our Platinum Sponsorship of the 2023 PDA Pharmaceutical Microbiology Conference,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems®.
  • Investors and other parties interested in attending in person are invited to register at: PDA Microbiology Conference 2023

Parenteral Drug Association and Euromed Communications release Industrial Pharmaceutical Microbiology Under New Collaboration

Retrieved on: 
Monday, September 25, 2023
FIP, Partnership, Book, Education, RPS, ABPI, Parenteral Drug Association, Multimedia, Science, PDA, EMA, Bio Products Laboratory, Publishing, Publication, Patient, Federation, Royal Pharmaceutical Society, FDA, EC, MHRA, Pharmaceutical industry

BETHESDA, Md., Sept. 25, 2023 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Standards & Controls (Sixth Edition), edited by Tim Sandle of Bio Products Laboratory, UK. This 700-page volume includes 25 chapters from 20 authors. Electronic copies are sold by both PDA and Euromed Communications and hardcopies exclusively by the latter company.

Key Points: 
  • BETHESDA, Md., Sept. 25, 2023 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Standards & Controls (Sixth Edition), edited by Tim Sandle of Bio Products Laboratory, UK.
  • Electronic copies are sold by both PDA and Euromed Communications and hardcopies exclusively by the latter company.
  • To learn more about this title and/or to purchase it, click here to the PDA Bookstore or the Euromed Communications store .
  • Over the years EC has built up close associations with various international pharmaceutical organisations such as the Royal Pharmaceutical Society (RPS), the Association of British Pharmaceutical Industries (ABPI), and the Federation of Industrial Pharmacists (FIP).

Innovation Takes Center Stage at the 2023 PDA Pharmaceutical Microbiology Conference

Retrieved on: 
Tuesday, September 12, 2023
Universe, GSK, Science, Human, Education, Pennsylvania State University, Risk management, Biomedical Research, Parenteral Drug Association, Research, Multimedia, Grand Hyatt Washington, Doctor of Philosophy, Regulator, Assistant, PDA, U.S. FDA, Environmental monitoring, Pandemic, Evaluation and Program Planning, Patient, FDA, Conference, Microbiology, Satellite navigation device, Pharmaceutical industry, Medical device, MD

BETHESDA, Md., Sept. 12, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA) announced today the 2023 PDA Pharmaceutical Microbiology Conference will feature innovative technologies as a main topic addressed throughout the agenda, October 2-4 at the Grand Hyatt Washington in Washington, DC.

Key Points: 
  • BETHESDA, Md., Sept. 12, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA) announced today the 2023 PDA Pharmaceutical Microbiology Conference will feature innovative technologies as a main topic addressed throughout the agenda, October 2-4 at the Grand Hyatt Washington in Washington, DC.
  • The 2023 PDA Pharmaceutical Microbiology Conference continues the ongoing tradition of addressing the opportunities and challenges to the future of microbiology in today's global market.
  • The 18th PDA Pharmaceutical Microbiology Conference concludes with the ever popular "Ask the Regulators" session, where U.S. FDA representatives will field questions posed by the audience.
  • Click here for more information on the 2023 PDA Pharmaceutical Microbiology Conference.

Parenteral Drug Association Announces Pulitzer Prize Winner Dominic Gates will speak at the 2023 PDA/FDA Joint Regulatory Conference

Retrieved on: 
Friday, September 1, 2023
Mathematics, Boeing, The Seattle Times, DC, Business, Parenteral Drug Association, E. W. Scripps Company, MAX, Science, PDA, Queen's University Belfast, Amazon, Pure mathematics, George Polk, Pulitzer Prize, Patient, Crash, Gates, Conference, Pharmaceutical industry

BETHESDA, Md., Sept. 1, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced Pulitzer Prize winning journalist Dominic Gates of the Seattle Times will present, "The Devastating Impact of Design and Manufacturing Quality Lapses at Boeing" during the second plenary session of the 2023 PDA/FDA Joint Regulatory Conference in Washington, DC, Sept. 18-20.

Key Points: 
  • BETHESDA, Md., Sept. 1, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced Pulitzer Prize winning journalist Dominic Gates of the Seattle Times will present, "The Devastating Impact of Design and Manufacturing Quality Lapses at Boeing" during the second plenary session of the 2023 PDA/FDA Joint Regulatory Conference in Washington, DC, Sept. 18-20.
  • PDA is very excited to have Mr. Gates join us at the 2023 PDA/FDA Joint Regulatory Conference to share such a compelling, although tragic, case-study on the life-and-death outcomes that poor quality practices and decisions can have.
  • Gates was a co-recipient of the 2020 Pulitzer Prize in National Reporting alongside Steve Miletich, Mike Baker, and Lewis Kamb for their coverage of the Boeing 737 MAX crashes and investigations.
  • For more information on the 2023 PDA/FDA Joint Regulatory Conference,

PDA and Innerspace Partner to Develop Training Courses Using Advanced Virtual Reality Simulators for Global Pharma Industry

Retrieved on: 
Monday, June 19, 2023
VR, PDA, Aseptic processing, Partnership, Parenteral Drug Association, Education, Oyster farming, Nursing, Innerspace

BETHESDA, Md., June 19, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) and Innerspace have announced a long-term strategic partnership to develop PDA training courses that incorporate the use of VR Simulators designed with frame-by-frame risk profiling capabilities. This partnership aims to create a series of hybrid lecture/VR data-driven, immersive, and effective training courses for professionals in the pharmaceutical and biopharmaceutical industries.

Key Points: 
  • BETHESDA, Md., June 19, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) and Innerspace have announced a long-term strategic partnership to develop PDA training courses that incorporate the use of VR Simulators designed with frame-by-frame risk profiling capabilities.
  • This partnership aims to create a series of hybrid lecture/VR data-driven, immersive, and effective training courses for professionals in the pharmaceutical and biopharmaceutical industries.
  • All PDA training courses are designed to meet the pharmaceutical industry's specific training needs and the health authorities' expectations.
  • "We are excited to initiate this partnership with Innerspace to deliver cutting-edge training courses for the pharmaceutical industry."

KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Retrieved on: 
Monday, February 27, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, KALV, University, University of Cincinnati, Anxiety, Annual general meeting, Parenteral Drug Association, Howard University Hospital, Hereditary angioedema, Critical care, UCLA School of Dentistry, AAAAI, Demand valve oxygen therapy, Division, HAE, University of Cincinnati Academic Health Center, David Geffen School of Medicine at UCLA, FAERS, Duke University Hospital, Tablet, OH, American Academy, Pharmaceutical industry, Medical device, Immunology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.
  • The following presentations occurred at the 2023 AAAAI Annual Meeting:
    A comparative bioavailability of sebetralstat following administration of orally disintegrating tablets and film-coated tablets in healthy volunteers: Michael D. Smith, KalVista Pharmaceuticals Inc., Cambridge, MA, USA
    Reporting of Adverse Drug Reactions with Parenteral Drugs for the On-Demand Treatment of Hereditary Angioedema Attacks – Analysis of the FAERS Database 2009 to 2022: Dr. Raffi Tachdjian, UCLA School of Medicine, Los Angeles, CA, USA
    Anxiety Associated With Parenteral On-Demand Treatment For Hereditary Angioedema (HAE): Dr.
  • Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, USA
    Patient Perspectives On Early Use Of On-Demand Treatment For Hereditary Angioedema (HAE) Attacks to Reduce Severity and Duration: Dr. Cristine Radojicic, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina, USA
    Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial: Dr. Jonathan A. Bernstein, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC, Cincinnati, OH, USA
    “The real-world data presented at AAAAI highlight the significant treatment burden and anxiety associated with existing injectable on-demand therapies, and the potential for sebetralstat, an investigational oral plasma kallikrein inhibitor, to improve the treatment experience for people living with HAE,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “Additionally highlighting this potential are the data from our phase 2 trial assessing sebetralstat for on-demand of HAE attacks demonstrating that early treatment decreased cumulative attack and symptom severity compared to placebo, as well as new data supporting continued advancement of our orally disintegrating tablet formulation.”

KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

Retrieved on: 
Thursday, February 16, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hereditary angioedema, Abstract, Q&A, HAE, KALV, Convention center, Route of administration, American Academy of Allergy, Asthma, and Immunology, Lancaster County Convention Center, Demand valve oxygen therapy, Poster, American Academy, Tablet, Anxiety, Parenteral Drug Association, FAERS, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27.
  • All results will be shared as a poster presentation and Q&A on Sunday, February 26 from 9:45-10:45 a.m. CST in the Convention Center, Lobby Level, Hall 2.
  • A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers (Poster #430): Michael D. Smith, Matt Iverson, Erik Hansen, Paul K. Audhya, Christopher M. Yea.
  • Anxiety Associated With Parenteral On-demand Treatment For Hereditary Angioedema (HAE) (Poster #433): Autumn Burnette, John Anderson, Hilary Longhurst, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga.